Hairy cell leukemia: a tumor of pre-plasma cells

Anderson, KC; Boyd, A W; Fisher, DC; Leslie, D; Schlossman, S F; Nadler, LM

doi:10.1182/blood.v65.3.620.bloodjournal653620

Cited by 14 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although this may contribute to the antileukemic activity of IFNa, on HC by potentiation of cytotoxic mechanisms, a differentiating or maturating effect of IFNa, on HC seems unlikely. Our results are in accordance with previous data (22) showing that B-cell restricted antigens and the plasma associated PCA-1 antigen are coexpressed on HC, but IFNa, did not induce a significant change in the number of cells expressing these antigens.…”

Section: Discussionsupporting

confidence: 93%

Interferon alpha‐2 for hairy cell leukemia: Evidence for induction of RNA synthesis in hairy cells and failure to correlate enhancement of natural killer cells with elimination of hairy cells

Schwarzmeier

Schwabe

Prischl

et al. 1987

European J of Haematology

View full text Add to dashboard Cite

The effect of human recombinant interferon α2 (IFNα2) on hairy cells obtained from 16 patients was evaluated. All patients promptly responded to induction of remission with 2 times 106 U/m2 interferon α2b, three times a week, sc. In order to achieve a more detailed insight into the mode of action of interferon in this disease, we determined the influence of IFNα2 on the incorporation of radiolabeled thymidine and uridine into hairy cells. While both 3H‐thymidine and 3H‐uridine incorporation were unaffected by IFNα2 in a 3‐hour incubation period, a significant increase in uridine incorporation into hairy cells, but not CLL cells, was observed after 24 h. Cell surface marker analysis performed with monoclonal antibodies did not reveal a quantitative alteration of the immunophenotype of hairy cells in vitro. In addition, natural killer cells, assessed by monoclonal antibodies and a cytotoxicity assay against K 562 cells, were found to be decreased in 9 out of 10 patients prior to therapy. Although IFNα2 could stimulate natural killer cells in vivo, we did not find a consistent correlation between the activation of these cells and the response to therapy. We conclude, therefore, that NK cells play no major role in the regression of hairy cells. Furthermore, IFNα2 does not alter antigenic determinants in vitro, but leads to an enhanced incorporation of 3H‐uridine into hairy cells in vitro, thus indicating a possible role for the induction of RNA synthesis in vivo.

show abstract

Section: Discussionsupporting

confidence: 93%

Interferon alpha‐2 for hairy cell leukemia: Evidence for induction of RNA synthesis in hairy cells and failure to correlate enhancement of natural killer cells with elimination of hairy cells

Schwarzmeier

Schwabe

Prischl

et al. 1987

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…Arrangement of the different chronic B cell malignancies in Figures 1 to 3 was based partly on their maturation stages as proposed by the knowledge from immunological marker studies (Anderson et al, 1984(Anderson et al, , 1985Ezdinli and Nanus, 1983;Lennert, 1978). The results suggest that the later stages of B-cell development is associated with an increase in 5'NT and PNP activities.…”

Section: Resultsmentioning

confidence: 76%

Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia

Knauf

Ganeshaguru

et al. 1987

Hematological Oncology

View full text Add to dashboard Cite

Previous reports have shown that the purine degradative enzymes adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP) and ecto-5'-nucleotidase (5'NT), play an important role in the normal development of lymphocytes and that investigations of these enzymes are of value in defining subsets of lymphoid malignancies of T-cell origin. Pharmacological inhibition of one of these enzymes has been found to be an effective treatment for a few lymphatic neoplasia. We have studied the activities of the above enzymes in the circulating malignant cells of 25 patients with B-chronic lymphatic leukemia (B-CLL), four patients with B prolymphocytic leukemia (PLL), seven patients with leukemic centrocytic lymphoma (CC), 18 patients with hairy cell leukemia (HCL) and 16 patients with immunocytoma (IC). For comparison, the blasts of nine patients with 'common' acute lymphatic leukemia (cALL) and normal T (n = 12) and B (n = 8) cells were simultaneously investigated. Despite morphologic similarity, the leukemic cells of the chronic B cell malignancies demonstrate different enzyme patterns. B-CLL is characterized by very low activities of all the enzymes ADA, PNP and 5'NT. In the cells of HCL the highest values of PNP are found. The leukemic cells of IC are characterized by low levels of ADA but moderate levels of PNP and high levels of 5'NT. Thus some of the entities of B malignancies show typical enzyme patterns which might be of importance in defining maturation stages of the disease. The differences in these enzyme patterns can also be made use of in therapy with enzyme inhibitors such as deoxycoformycin.

show abstract

“…Further experiments need to be done to determine which cell(s) within the myeloma clone can be triggered by growth factors. Recently described techniques for the culture of myeloma cells (37), coupled with the above described responses to lymphokines and with newer techniques of multiple fluorochrome immunofluorescence analysis that have proven useful for the study of both normal and neoplastic B cells (51,52), may permit the phenotypic definition of those myeloma cells which have the capacity to proliferate in response to growth factor or those "clonogenic cells" with self-renewal capacity. Phenotypic purification of such cells using these techniques may both facilitate their biological characterization and suggest improved methods of in vitro depletion to be utilized prior to autologous BMT for plasma cell dyscrasias.…”

Section: Discussionmentioning

confidence: 99%

Autologous bone marrow transplantation therapy for multiple myeloma

Anderson

Barut

Ritz

et al. 1989

European J of Haematology

View full text Add to dashboard Cite

We have begun an autologous bone marrow transplantation (ABMT) treatment protocol for patients with myeloma who achieve a minimal disease (< loolo marrow plasma cells) status. Sites of bony disease are irradiated before BMT. Melphalan 70 mg/m2 on days 1 and 2 is followed by 1200 rads total-body irradiation administered in fractionated doses over 3 d. Autologous marrow which has been previously treated with anti-CALLA, B1, and PCA-1 monoclonal antibodies is then thawed and reinfused. 4 males and 2 females with median age of 46 yr (41-56) have been treated. Granulocytes

show abstract

Hairy cell leukemia: a tumor of pre-plasma cells

Cited by 14 publications

References 0 publications

Interferon alpha‐2 for hairy cell leukemia: Evidence for induction of RNA synthesis in hairy cells and failure to correlate enhancement of natural killer cells with elimination of hairy cells

Interferon alpha‐2 for hairy cell leukemia: Evidence for induction of RNA synthesis in hairy cells and failure to correlate enhancement of natural killer cells with elimination of hairy cells

Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia

Autologous bone marrow transplantation therapy for multiple myeloma

Contact Info

Product

Resources

About